In 2007 Amylin Pharmaceuticals issued 3.00% convertible senior notes due 2014. The Note Indenture gives the noteholders the right to demand redemption of any or all of their notes at face value upon the occurrence of "Fundamental Change," which occurs, among other time, when “the Continuing Directors do not constitute a majority of the Company’s Board of Directors . . . .” The Indenture defines “Continuing Directors” as follows: (i) individuals who on the Issue Date constituted the Board of Directors and (ii) any new directors whose election to the Board of Directors or whose nomination for election by the stockholders of the Company was approved by at least a majority of the directors then still in office (or a duly constituted committee thereof) either who were directors on the Issue Date or whose election or nomination for election was previously so approved.
Este resumen lo hemos tomado de aquí
Y el juez, tras decir que la cláusula era válida, dice